Developer docs
API playgroundTry for free, no card

Search company profiles

Remsleep Holdings

Full company profile

uuid0006eaz

Namestring
Remsleep Holdings
Legal namestring
RemSleep Holdings, Inc.
Websiteurl
remsleep.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

RemSleep Holdings, Inc. (OTCQB: RMSL) is a publicly traded US medical device company headquartered in Orlando, Florida, focused exclusively on the DeltaWave nasal pillow CPAP mask system for the treatment of obstructive, central, and complex sleep apnea as well as comorbid respiratory conditions including congestive heart failure, neuromuscular disease, and COPD. The DeltaWave is a miniaturized nasal pillow interface cleared by the FDA under 510(k) (initial clearance in 2025; expanded clearance K253939 in January 2026) for use with all non-invasive positive airway pressure devices — not just CPAP — across both home and institutional settings including hospitals, long-term care facilities, rehabilitation centers, and sleep laboratories.

The company operates a single-product, hardware-sales revenue model, commercializing DeltaWave through a direct sales network covering 48 states targeting institutional healthcare buyers alongside home-care CPAP channels. Pricing is not publicly disclosed and is quote-based. Early market signals include a 70-unit deployment by an early adopting provider with zero returns and repeat orders. Management is targeting 1,500–1,600 units per month as an initial sustainable volume benchmark and is publicly exploring capital-raising options to fund continued growth.

RemSleep is a microcap (approximately $12.8M valuation as of January 2026) with 11–50 employees, no disclosed institutional venture funding, and recent leadership transition: following the passing of founder/Chairman/CEO Thomas Wood in February 2026, Anita Michaels was appointed Chairman, Jeffrey Marshall became CEO, and Alexander Johnson joined as Director. The company reported 2025 revenue of $16,721 against an operating loss of approximately $2.77M, reflecting the pre-commercialization buildout phase that preceded the 2025–2026 FDA and sales infrastructure activation.

Short descriptiontext

RemSleep Holdings is a US public microcap medical device company that designs and commercializes the FDA-cleared DeltaWave nasal pillow CPAP mask system for sleep apnea and respiratory treatment across home-care and institutional healthcare channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
CPAP mask systems, sleep apnea treatment, nasal pillow interface, respiratory medical devices, non-invasive ventilation
Industry2 codes
1Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV)
CodeHLAHAGAAPrimaryYes
2Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers)
CodeHSABAKADPrimaryNo
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sleep Apnea Treatment Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1DeltaWave CPAP Mask Hardware Sales
TypeHardware Sales
Description

Primary revenue stream from sale of the FDA-cleared DeltaWave nasal pillow CPAP mask system. Early market signals indicate strong retention and repeat orders, with one early adopting provider reporting zero returns across a 70-unit deployment. Company targets 1,500-1,600 units per month as initial sustainable volume benchmark.

einpresswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Pricing details1 tier
1Pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed

vvdailypress.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1DeltaWave
Description

Nasal pillow CPAP mask system for sleep apnea treatment, cleared by FDA for home and institutional use.

in.investing.com
Core offering1 text field

RemSleep Holdings designs and manufactures the DeltaWave nasal pillow CPAP mask system, an FDA 510(k)-cleared (K253939) medical device for sleep apnea and related respiratory conditions. The product is sold to institutional healthcare providers (hospitals, long-term care, rehabilitation centers, sleep laboratories) and home-based CPAP therapy channels, and is cleared for use with all non-invasive positive airway devices across multiple patient populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Zero returns across 70-unit deployment with repeat orders
Product overview1 text field

Remsleep Holdings is a single-product medical device company focused on its DeltaWave CPAP mask system. The DeltaWave is a nasal pillow CPAP mask cleared by the FDA for sleep apnea treatment. The company recently received expanded FDA 510(k) clearance in January 2026, extending use from home-based therapy to institutional settings and broadening the indicated patient population to include central sleep apnea, complex sleep apnea, congestive heart failure, neuromuscular diseases, and COPD. The company is transitioning from infrastructure buildout to active market execution, targeting 1,500-1,600 units per month as an initial sustainable volume benchmark.

Product and service1 record
1DeltaWave nasal pillow CPAP mask system
CategorySleep apnea treatment devices
Description

The DeltaWave nasal pillow CPAP mask system is the company's FDA 510(k)-cleared (K253939) medical device for non-invasive positive airway pressure therapy. It features a micro-sized nasal pillow interface and is intended for use with CPAP, BiPAP, and other non-invasive positive airway devices. The product is sold to institutional healthcare providers (hospitals, long-term care facilities, rehabilitation centers, sleep laboratories) and home-based CPAP therapy patients for the treatment of obstructive sleep apnea, central sleep apnea, complex sleep apnea, congestive heart failure, neuromuscular diseases, and COPD.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global market leader in sleep apnea and CPAP devices, with the broadest CPAP mask portfolio (AirFit, AirTouch) including nasal pillow lines. Directly comparable as a CPAP mask and sleep apnea therapy competitor; far larger and more diversified.

TypeBroad incumbent
Description

Leading manufacturer of nasal pillow CPAP masks (Brevida, F&P Nova) and a major player in hospital respiratory care. Directly comparable on nasal pillow design and on institutional/hospital respiratory product overlap.

3Apex Medical
TypeDirect peer
Description

Designs and manufactures CPAP/BiPAP devices and masks, including nasal pillow interfaces used in both home and clinical sleep therapy. Closely comparable as a CPAP mask manufacturer operating in the same indications and channels.

TypeEmerging player
Description

Smaller specialty manufacturer of CPAP interfaces including nasal pillow and cloth-based mask systems. Comparable as a niche CPAP mask designer targeting sleep apnea patients with comfort/differentiation messaging.

TypeDirect peer
Description

Chinese medical device manufacturer with a global CPAP/BiPAP and mask line including nasal pillow products. Comparable as a competing CPAP mask brand targeting sleep apnea and respiratory conditions in home and institutional settings.

TypeBroad incumbent
Description

Broad-line respiratory and sleep therapy manufacturer producing CPAP/BiPAP devices and masks (including nasal pillow forms). Comparable through its CPAP product line and home/institutional distribution footprint.

TypeBroad incumbent
Description

Major incumbent in CPAP masks, BiPAP, and hospital ventilation with the DreamWear nasal pillow line as a direct competitive product. Comparable across both home and institutional channels; significantly larger and currently navigating CPAP recall-related product transitions.

TypeDirect peer
Description

U.S. CPAP device and mask manufacturer focused on sleep apnea and respiratory care with both consumer and clinical channels. Comparable as a similarly-sized competitor in CPAP mask and device commercialization.

9Transcend / Somnetics International
TypeDirect peer
Description

Manufacturer of compact CPAP devices and compatible mask interfaces for sleep apnea therapy. Comparable as a smaller, single-category CPAP equipment competitor pursuing the home and travel therapy channel.

TypeEmerging player
Description

Respiratory and sleep therapy provider offering CPAP masks, devices, and related supplies to home and clinical customers. Comparable as a mid-sized CPAP mask and equipment distributor/manufacturer operating in overlapping channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Remsleep Holdings

Sleep Apnea Treatment Devicesremsleep.com

RemSleep Holdings is a US public microcap medical device company that designs and commercializes the FDA-cleared DeltaWave nasal pillow CPAP mask system for sleep apnea and respiratory treatment across home-care and institutional healthcare channels.

What Remsleep Holdings does

RemSleep Holdings, Inc. (OTCQB: RMSL) is a publicly traded US medical device company headquartered in Orlando, Florida, focused exclusively on the DeltaWave nasal pillow CPAP mask system for the treatment of obstructive, central, and complex sleep apnea as well as comorbid respiratory conditions including congestive heart failure, neuromuscular disease, and COPD. The DeltaWave is a miniaturized nasal pillow interface cleared by the FDA under 510(k) (initial clearance in 2025; expanded clearance K253939 in January 2026) for use with all non-invasive positive airway pressure devices — not just CPAP — across both home and institutional settings including hospitals, long-term care facilities, rehabilitation centers, and sleep laboratories.

The company operates a single-product, hardware-sales revenue model, commercializing DeltaWave through a direct sales network covering 48 states targeting institutional healthcare buyers alongside home-care CPAP channels. Pricing is not publicly disclosed and is quote-based. Early market signals include a 70-unit deployment by an early adopting provider with zero returns and repeat orders. Management is targeting 1,500–1,600 units per month as an initial sustainable volume benchmark and is publicly exploring capital-raising options to fund continued growth.

RemSleep is a microcap (approximately $12.8M valuation as of January 2026) with 11–50 employees, no disclosed institutional venture funding, and recent leadership transition: following the passing of founder/Chairman/CEO Thomas Wood in February 2026, Anita Michaels was appointed Chairman, Jeffrey Marshall became CEO, and Alexander Johnson joined as Director. The company reported 2025 revenue of $16,721 against an operating loss of approximately $2.77M, reflecting the pre-commercialization buildout phase that preceded the 2025–2026 FDA and sales infrastructure activation.

Remsleep Holdings firmographics

Firmographics
Name
Remsleep Holdings
Legal name
RemSleep Holdings, Inc.
Website
https://remsleep.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
RemSleep Holdings is a US public microcap medical device company that designs and commercializes the FDA-cleared DeltaWave nasal pillow CPAP mask system for sleep apnea and respiratory treatment across home-care and institutional healthcare channels.
Ownership category
akta.pro rank

Remsleep Holdings industry classification

Industry
Product category
Sleep Apnea Treatment Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)
akta.pro secondary industry
Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers) (HSABAKAD)

Keywords

  • CPAP mask systems
  • Sleep apnea treatment
  • Nasal pillow interface
  • Respiratory medical devices
  • Non-invasive ventilation

Where Remsleep Holdings is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Markets served

Remsleep Holdings business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. DeltaWave CPAP Mask Hardware Sales: Primary revenue stream from sale of the FDA-cleared DeltaWave nasal pillow CPAP mask system. Early market signals indicate strong retention and repeat orders, with one early adopting provider reporting zero returns across a 70-unit deployment. Company targets 1,500-1,600 units per month as initial sustainable volume benchmark.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing not publicly disclosed

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Remsleep Holdings product offering

Product offering

Core offering

RemSleep Holdings designs and manufactures the DeltaWave nasal pillow CPAP mask system, an FDA 510(k)-cleared (K253939) medical device for sleep apnea and related respiratory conditions. The product is sold to institutional healthcare providers (hospitals, long-term care, rehabilitation centers, sleep laboratories) and home-based CPAP therapy channels, and is cleared for use with all non-invasive positive airway devices across multiple patient populations.

Product overview

Remsleep Holdings is a single-product medical device company focused on its DeltaWave CPAP mask system. The DeltaWave is a nasal pillow CPAP mask cleared by the FDA for sleep apnea treatment. The company recently received expanded FDA 510(k) clearance in January 2026, extending use from home-based therapy to institutional settings and broadening the indicated patient population to include central sleep apnea, complex sleep apnea, congestive heart failure, neuromuscular diseases, and COPD. The company is transitioning from infrastructure buildout to active market execution, targeting 1,500-1,600 units per month as an initial sustainable volume benchmark.

Differentiator

Problem solved

Functional benefit

Brands

  • DeltaWave: Nasal pillow CPAP mask system for sleep apnea treatment, cleared by FDA for home and institutional use.

Products and services

  • DeltaWave nasal pillow CPAP mask system The DeltaWave nasal pillow CPAP mask system is the company's FDA 510(k)-cleared (K253939) medical device for non-invasive positive airway pressure therapy. It features a micro-sized nasal pillow interface and is intended for use with CPAP, BiPAP, and other non-invasive positive airway devices. The product is sold to institutional healthcare providers (hospitals, long-term care facilities, rehabilitation centers, sleep laboratories) and home-based CPAP therapy patients for the treatment of obstructive sleep apnea, central sleep apnea, complex sleep apnea, congestive heart failure, neuromuscular diseases, and COPD.

Quantifiable outcome

  • Zero returns across 70-unit deployment with repeat orders

Companies that use Remsleep Holdings

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Remsleep Holdings technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Remsleep Holdings partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Remsleep Holdings competitors and assessment

Company assessment

Broad incumbents

  • ResMed: Global market leader in sleep apnea and CPAP devices, with the broadest CPAP mask portfolio (AirFit, AirTouch) including nasal pillow lines. Directly comparable as a CPAP mask and sleep apnea therapy competitor; far larger and more diversified.
  • Fisher & Paykel Healthcare: Leading manufacturer of nasal pillow CPAP masks (Brevida, F&P Nova) and a major player in hospital respiratory care. Directly comparable on nasal pillow design and on institutional/hospital respiratory product overlap.
  • Drive DeVilbiss Healthcare: Broad-line respiratory and sleep therapy manufacturer producing CPAP/BiPAP devices and masks (including nasal pillow forms). Comparable through its CPAP product line and home/institutional distribution footprint.
  • Philips Respironics: Major incumbent in CPAP masks, BiPAP, and hospital ventilation with the DreamWear nasal pillow line as a direct competitive product. Comparable across both home and institutional channels; significantly larger and currently navigating CPAP recall-related product transitions.

Direct peers

  • Apex Medical: Designs and manufactures CPAP/BiPAP devices and masks, including nasal pillow interfaces used in both home and clinical sleep therapy. Closely comparable as a CPAP mask manufacturer operating in the same indications and channels.
  • BMC Medical: Chinese medical device manufacturer with a global CPAP/BiPAP and mask line including nasal pillow products. Comparable as a competing CPAP mask brand targeting sleep apnea and respiratory conditions in home and institutional settings.
  • 3B Medical: U.S. CPAP device and mask manufacturer focused on sleep apnea and respiratory care with both consumer and clinical channels. Comparable as a similarly-sized competitor in CPAP mask and device commercialization.
  • Transcend / Somnetics International: Manufacturer of compact CPAP devices and compatible mask interfaces for sleep apnea therapy. Comparable as a smaller, single-category CPAP equipment competitor pursuing the home and travel therapy channel.

Emerging players

  • Circadiance: Smaller specialty manufacturer of CPAP interfaces including nasal pillow and cloth-based mask systems. Comparable as a niche CPAP mask designer targeting sleep apnea patients with comfort/differentiation messaging.
  • React Health (formerly 3B Medical / CPAP retail assets): Respiratory and sleep therapy provider offering CPAP masks, devices, and related supplies to home and clinical customers. Comparable as a mid-sized CPAP mask and equipment distributor/manufacturer operating in overlapping channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Remsleep Holdings social profiles

Digital presence

Remsleep Holdings compliance and trust

Trust signal

Compliance1 record

Remsleep Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Remsleep Holdings leadership team

Management profile

Number of profiles

Profiles3 records

Remsleep Holdings funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Remsleep Holdings M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Remsleep Holdings

What does Remsleep Holdings do?

RemSleep Holdings designs and manufactures the DeltaWave nasal pillow CPAP mask system, an FDA 510(k)-cleared (K253939) medical device for sleep apnea and related respiratory conditions. The product is sold to institutional healthcare providers (hospitals, long-term care, rehabilitation centers, sleep laboratories) and home-based CPAP therapy channels, and is cleared for use with all non-invasive positive airway devices across multiple patient populations.

Is Remsleep Holdings a public or private company?

Remsleep Holdings is a public company. It is classified as public and is currently operating.

When was Remsleep Holdings founded?

Remsleep Holdings was founded in 2007. It employs 11 to 50 people.

Where is Remsleep Holdings based?

Remsleep Holdings is headquartered in Orlando, United States, in the North America region.

How does Remsleep Holdings make money?

One revenue line is on record: deltaWave CPAP Mask Hardware Sales.

Who are Remsleep Holdings's main competitors?

Broad incumbents on record are ResMed, Fisher & Paykel Healthcare, Drive DeVilbiss Healthcare and Philips Respironics. Direct peers are Apex Medical, BMC Medical, 3B Medical and Transcend / Somnetics International. Emerging players are Circadiance and React Health (formerly 3B Medical / CPAP retail assets).

Does Remsleep Holdings have an API?

No public API is recorded for Remsleep Holdings.

What industry is Remsleep Holdings in?

Remsleep Holdings's product category is Sleep Apnea Treatment Devices. Its primary akta.pro industry code is HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV), with a secondary code of HSABAKAD, Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comRemSleep Holdings announces leadership changes following CEO’s passing By Investing.comRemSleep Holdings announced leadership changes on February 26, 2026, following the passing of its founder, Chairman, and CEO Thomas Wood. The company appointed Anita Michaels, Wood's sister and sole surviving board member, as Chairman, Jeffrey Marshall as CEO, and Alexander Johnson as director, with all appointments ratified by unanimous written consent. The new leadership appointments include an executive employment agreement with Marshall featuring performance-based equity compensation of up to 7% of fully diluted capitalization.TradingViewRemSleep names Jeffrey Marshall CEO; Anita Michaels becomes ChairmanRemSleep Holdings Inc. appointed Jeffrey Marshall as Chief Executive Officer and Director, and Anita Michaels as Chairman of the Board, effective March 2, 2026, following the passing of founder Thomas Wood who had held both positions. Alexander Johnson was also appointed as Director as part of the board reconstitution. Marshall brings over 40 years of healthcare clinical and administrative experience, while Michaels, who was previously Chief Operating Officer and majority shareholder, led the board restructuring.Investing.comREMSleep receives FDA clearance for expanded DeltaWave use By Investing.comREMSleep Holdings, Inc. (OTCQB:RMSL) announced it has received expanded FDA 510(k) clearance (K253939) for its DeltaWave nasal pillow system, extending use from home-based CPAP therapy to institutional settings including hospitals, long-term care facilities, rehabilitation centers, and sleep laboratories. The supplemental clearance also broadens the indicated patient population to include those with central sleep apnea, complex sleep apnea, congestive heart failure, neuromuscular diseases, and COPD, and allows use with all non-invasive positive airway devices rather than CPAP machines only. The microcap company, valued at approximately $12.8 million, submitted the supplemental application in early December 2025 following feedback from sleep lab directors and hospital respiratory therapists during a late 2025 soft launch.Victorville Daily PressREMSleep Outlines Q1 2026 Commercial Strategy: Expanded FDA Application, B2B Launch Prep, and Institutional Market EntryREMSleep Holdings outlined its Q1 2026 commercial strategy as it transitions from infrastructure buildout to active market execution with its FDA-cleared DeltaWave CPAP mask system. The company submitted a supplemental 510(k) application in December 2025 seeking FDA clearance to expand DeltaWave's use beyond traditional CPAP therapy to include BiPAP and other positive pressure ventilation devices as well as institutional hospital settings. Management is targeting 1,500–1,600 units per month as an initial sustainable volume benchmark while exploring capital-raising options to fund continued growth.EIN PresswireREMSleep's DeltaWave System Gains Early Traction as Sales Infrastructure ActivatesREMSleep Holdings, Inc. announced early market traction for its DeltaWave CPAP mask system as its sales infrastructure shifts to active commercialization. Early customer feedback shows strong retention and repeat orders, with initial indications that the product performs according to its brand promise.EIN PresswireREMSleep Completes Critical Infrastructure Milestones Ahead of Q1 2026 Commercial PushREMSleep Holdings Inc. has completed critical infrastructure milestones to support commercialization of its FDA-cleared DeltaWave™ CPAP mask system, including activating a nationwide sales network covering 48 states and implementing an enterprise ERP system. Early market signals are positive, with one early adopting provider reporting zero returns across a 70-unit deployment and repeat orders, while the company targets sustainable monthly volumes of 1,500-1,600 units. The company also has a second 510(k) application under FDA review for expanded indications including BiPAP and positive pressure ventilation applications.GlobeNewswireREMSleep Holdings, Inc. Shareholder UpdateREMSleep Holdings delayed the Deltawave nasal pillows mask launch to end of January 2025, citing product arrival and FDA compliance. The company secured two distributors and is upgrading its website and developing new molds for future products.TradingViewRemSleep Holdings Inc. SEC 10-Q ReportRemSleep Holdings reported Q3 2024 revenue of $37,260, down from $51,947 in 2023, and a net loss of $277,909. The company received FDA 510k approval for its DeltaWave CPAP interface and plans to have inventory ready in Q4 2024. It aims to capture 10% of the market in 24 months but faces going-concern doubts.GlobeNewswireREMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System SamplesREMSleep Holdings announced that a CPAP industry distributor requested samples of its DELTAWAVE Nasal Pillows System. The company is preparing the samples for shipment, and CEO Tom Wood said the request marks a milestone. REMSleep will keep shareholders updated on progress.GlobeNewswireREMSleep Holdings Inc. Receives 510(K) Clearance on ProductREMSleep Holdings received FDA 510(k) clearance for its Deltawave CPAP pillows interface, a Class II device. The company will now prepare the product for market, including website updates, inventory, and distributor outreach. It also noted short interest and potential naked short sales, committing to monitor and act.